NASDAQ:IRMD - Iradimed Stock Price, News & Analysis

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

Iradimed Corp (NASDAQ:IRMD) posted its earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The medical equipment provider had revenue of $7.62 million for the quarter, compared to analysts' expectations of $7.43 million. Iradimed had a net margin of 23.92% and a return on equity of 14.78%. View Iradimed's Earnings History.

Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Iradimed.

Iradimed issued an update on its third quarter 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of $0.14-0.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $9.7-10 million, compared to the consensus revenue estimate of $9.84 million.

1 Wall Street analysts have issued 12-month target prices for Iradimed's shares. Their predictions range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price. View Analyst Price Targets for Iradimed.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Media stories about IRMD stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iradimed earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Iradimed.

Iradimed saw a decrease in short interest during the month of August. As of August 15th, there was short interest totalling 457,700 shares, a decrease of 13.2% from the July 15th total of 527,200 shares. Based on an average daily trading volume, of 78,800 shares, the short-interest ratio is presently 5.8 days. Approximately 9.3% of the shares of the stock are short sold. View Iradimed's Current Options Chain.

Some companies that are related to Iradimed include Luminex (LMNX), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD), AtriCure (ATRC), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX), Cerus (CERS), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), AngioDynamics (ANGO), SurModics (SRDX), MiMedx Group (MDXG), Antares Pharma (ATRS), Intersect ENT (XENT) and Orthopediatrics (KIDS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), Micron Technology (MU), Palo Alto Networks (PANW), BioTelemetry (BEAT), Cisco Systems (CSCO), Alphabet (GOOG), IntriCon (IIN), GrubHub (GRUB) and Mastercard (MA).

Iradimed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Atria Investments LLC (6.92%), Atria Investments LLC (6.79%), BlackRock Inc. (3.44%), Renaissance Technologies LLC (3.20%), Vanguard Group Inc. (2.43%) and RK Capital Management LLC (1.70%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

IRMD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Acadian Asset Management LLC, Victory Capital Management Inc., Cadence Capital Management LLC, LPL Financial LLC, GSA Capital Partners LLP, Fiera Capital Corp and Wells Fargo & Company MN. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

IRMD stock was bought by a variety of institutional investors in the last quarter, including Atria Investments LLC, Atria Investments LLC, Marshall Wace LLP, RK Capital Management LLC, BlackRock Inc., Mondrian Investment Partners LTD, Renaissance Technologies LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Iradimed.

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRMD stock can currently be purchased for approximately $23.09.

Iradimed has a market capitalization of $262.53 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.View Additional Information About Iradimed.

The official website for Iradimed is http://www.iradimed.com/.

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]